# GLYCYX MOR, INC.: A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1CPS >1)

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | GLYCYX MOR, INC. |
| Location | SAN FRANCISCO, CA |
| Project | A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1CPS >1) |
| Project number | 5R44CA306565-02 |
| Mechanism | R44 |
| Institute | National Cancer Institute |
| Award | $1,047,803 |
| Awarded | 2026-09-14 |
| Project period | 2025-09-19 to 2027-08-31 |
| UEI | C2B7XPCFTHC7 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11418514). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.